AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test (STS)
Number of subjects: 39
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower body strength measures
Number of subjects: 39
Study 33686559 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 30
Study 33686573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 86
Study 33686574 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening using community health workers (CHWs)
Number of subjects: 60
Study 33686631 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day for mild renal impairment, 0.75 mg/day for moderate renal impairment, 0.5 mg/day for severe renal impairment)
Number of subjects: 34
Study 33686631 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (0.5 mg/day for severe renal impairment)
Number of subjects: 34
Study 33686631 — intervention group
Group type: COMPARATOR
Intervention: Normal renal function (control group)
Number of subjects: 34
Study 33686914 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV 2016-2017 strains
Number of subjects: 0
Study 33686914 — intervention group
Group type: COMPARATOR
Intervention: DENV 2013-2014 strains
Number of subjects: 0
Study 33687069 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 11232
Study 33687069 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 11232
Study 33687069 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 11232
Study 33687069 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 11232
Study 33687163 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg per day)
Number of subjects: 320
Study 33687163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 33687554 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT)
Number of subjects: 43
Study 33687667 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for ECoG electrodes recognition.
Number of subjects: 24
Study 33687667 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for simultaneous recognition of depth and ECoG electrodes.
Number of subjects: 24
Study 33687687 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI; Acthar) 80 U subcutaneously every other day through week 4, then twice weekly through week 24
Number of subjects: 0
Study 33687687 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI; Acthar)
Number of subjects: 0
Study 33687687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33687761 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite sensitization
Number of subjects: 0
Study 33687761 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 0
Study 33687761 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 0
Study 33687786 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C11-511
Number of subjects: 39
Study 33687786 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C11-511 (>75th percentile)
Number of subjects: 39
Study 33688022 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg two times per day co-administered with durvalumab 1500 mg Q4W
Number of subjects: 32
Study 33688091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lung disease
Number of subjects: 0
Study 33688091 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 0
Study 33688091 — intervention group
Group type: COMPARATOR
Intervention: No chronic lung disease
Number of subjects: 0
Study 33688228 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120mg three times daily) and Phentermine (37.5mg once daily)
Number of subjects: 114
Study 33688228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily) and Phentermine (37.5mg once daily)
Number of subjects: 114
Study 33688228 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat/phentermine
Number of subjects: 114
Study 33688228 — intervention group
Group type: COMPARATOR
Intervention: Placebo/phentermine
Number of subjects: 114
Study 33688228 — intervention group
Group type: COMPARATOR
Intervention: Phentermine alone
Number of subjects: 114
Study 33688276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) using the Sonata system
Number of subjects: 500
Study 33688276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA)
Number of subjects: 500
Study 33688615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training for 10 weeks
Number of subjects: 12
Study 33688640 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 0
Study 33688640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri/tetracyclic antidepressants + SGA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: FGA + MSA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: FGA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI + SGA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + MSA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + SGA
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: No drug
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion + SSRI
Number of subjects: 529359
Study 33688834 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy alone (without medication)
Number of subjects: 529359
Study 33688844 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based wellness platform (My Viva Plan)
Number of subjects: 97
Study 33688844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to MVP)
Number of subjects: 97
Study 33688857 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown period
Number of subjects: 76
Study 33689033 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PLA
Number of subjects: 7
Study 33689033 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-EV+
Number of subjects: 7
Study 33689033 — intervention group
Group type: COMPARATOR
Intervention: Post-EV-
Number of subjects: 7
Study 33689063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium (HS) diet (300 mEq/day) for 6 days
Number of subjects: 14
Study 33689063 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium (LS) diet (10 mEq/day) for 6 days
Number of subjects: 14
Study 33689985 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing of borderline SARS-CoV-2 patients using rRT-PCR
Number of subjects: 107
Study 33689985 — intervention group
Group type: COMPARATOR
Intervention: Borderline SARS-CoV-2 test results
Number of subjects: 107
Study 33689985 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall positive SARS-CoV-2 samples in the follow-up group
Number of subjects: 107
Study 33691074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Teledermatology
Number of subjects: 0
Study 33691182 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Messages
Number of subjects: 0
Study 33691262 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS-010 at a dose of 240 mg Q2W
Number of subjects: 289
Study 33691262 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS-010 at doses of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W
Number of subjects: 289
Study 33691305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic opioid use
Number of subjects: 22844
Study 33691305 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drug classes
Number of subjects: 22844
Study 33691305 — intervention group
Group type: EXPERIMENTAL
Intervention: TADL
Number of subjects: 22844
Study 33691309 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal QRS axis in newborns
Number of subjects: 12317
Study 33691309 — intervention group
Group type: COMPARATOR
Intervention: Sex (boys vs girls)
Number of subjects: 12317
Study 33691309 — intervention group
Group type: COMPARATOR
Intervention: Gestational age (GA)
Number of subjects: 12317
Study 33691309 — intervention group
Group type: COMPARATOR
Intervention: Infant size
Number of subjects: 12317
Study 33691309 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS axis intervals
Number of subjects: 12317
Study 33691480 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab, dosage and duration not specified
Number of subjects: 0
Study 33691765 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation (LMWH or UFH)
Number of subjects: 462
Study 33691765 — intervention group
Group type: COMPARATOR
Intervention: Standard care (thromboprophylactic doses of LMWH or UFH)
Number of subjects: 462
Study 33692132 — intervention group
Group type: EXPERIMENTAL
Intervention: siBcl2L12-SNAs (NU-0129) administered intravenously at a dose corresponding to 1/50th of the no-observed-adverse-event level
Number of subjects: 0
Study 33692132 — intervention group
Group type: EXPERIMENTAL
Intervention: siBcl2L12-SNAs (NU-0129) administered intravenously
Number of subjects: 0
Study 33692676 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33692727 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for radiographers; details on dosage and duration not available
Number of subjects: 0
Study 33693009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen
Number of subjects: 0
Study 33693009 — intervention group
Group type: COMPARATOR
Intervention: Control (standard oxygen therapy)
Number of subjects: 0
Study 33693520 — intervention group
Group type: EXPERIMENTAL
Intervention: eREE-CKD equation
Number of subjects: 300
Study 33693709 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM with depressive symptoms
Number of subjects: 1843
Study 33693709 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT with depressive symptoms
Number of subjects: 1843
Study 33693709 — intervention group
Group type: COMPARATOR
Intervention: GDM without depressive symptoms
Number of subjects: 1843
Study 33693709 — intervention group
Group type: COMPARATOR
Intervention: NGT without depressive symptoms
Number of subjects: 1843
Study 33693736 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple hormonal and metabolic deficiency syndrome (MHDS)
Number of subjects: 480
Study 33693736 — intervention group
Group type: COMPARATOR
Intervention: No multiple hormonal and metabolic deficiency syndrome (NO-MHDS)
Number of subjects: 480
Study 33693776 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg gliclazide
Number of subjects: 16
Study 33693781 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 9
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 961
Study 33693813 — intervention group
Group type: COMPARATOR
Intervention: No Vitamin D supplements
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collection in summer or fall
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfall birth season
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to higher 25(OH)D
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary intake of Vitamin D
Number of subjects: 961
Study 33693813 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater waist circumference (among black children only)
Number of subjects: 961
Study 33693943 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HIV antibodies
Number of subjects: 0
Study 33693990 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (off-label use in 44% of cases)
Number of subjects: 152
Study 33693990 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 152
Study 33694071 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 exposure
Number of subjects: 14600
Study 33694071 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 illness
Number of subjects: 14600
Study 33694071 — intervention group
Group type: EXPERIMENTAL
Intervention: Job burnout
Number of subjects: 14600
Study 33694071 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and emotional distress
Number of subjects: 14600
Study 33694071 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of COVID-19 illness by race/ethnicity
Number of subjects: 14600
Study 33694084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysophosphatidylethanolamine acyltransferase (LPEAT) levels in patients with severe CAP (SCAP)
Number of subjects: 267
Study 33694084 — intervention group
Group type: EXPERIMENTAL
Intervention: LPEAT levels in patients stratified by PSI and CURB-65 scores
Number of subjects: 267
Study 33694084 — intervention group
Group type: EXPERIMENTAL
Intervention: LPEAT as a predictor of SCAP in patients with CAP
Number of subjects: 267
Study 33694084 — intervention group
Group type: EXPERIMENTAL
Intervention: LPEAT in predicting 30-day mortality rate in patients with CAP
Number of subjects: 267
Study 33694093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 292
Study 33694093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 292
Study 33694093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 33694122 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (age group not specified)
Number of subjects: 211
Study 33694122 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (age group not specified)
Number of subjects: 211
Study 33694122 — intervention group
Group type: EXPERIMENTAL
Intervention: Women under 55 years
Number of subjects: 211
Study 33694122 — intervention group
Group type: COMPARATOR
Intervention: Men under 55 years
Number of subjects: 211
Study 33694122 — intervention group
Group type: COMPARATOR
Intervention: Overall population (men and women)
Number of subjects: 211
Study 33694257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (starting dose 2 mg/kg/day on days 1-21 of each 28-day cycle for a maximum of 12 cycles)
Number of subjects: 17
Study 33694368 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain oat intake
Number of subjects: 0
Study 33694368 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii presence
Number of subjects: 0
Study 33694368 — intervention group
Group type: COMPARATOR
Intervention: Germ-free (GF) mice
Number of subjects: 0
Study 33694368 — intervention group
Group type: EXPERIMENTAL
Intervention: F. prausnitzii-monocolonized mice
Number of subjects: 0
Study 33704027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) Change Package
Number of subjects: 1200
Study 33704027 — intervention group
Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 1200
Study 33704071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin 150 mg
Number of subjects: 300
Study 33704071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin 300 mg
Number of subjects: 300
Study 33704071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 33704074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vision reading rehabilitation using magnification for 3 weeks
Number of subjects: 150
Study 33704077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes remote monitoring program facilitated by cellular-connected glucose meter and phone-based diabetes coaching provided by Livongo Health.
Number of subjects: 119
Study 33704077 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) before intervention.
Number of subjects: 119
Study 33704077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes remote monitoring program after usual care (IV/UC).
Number of subjects: 119
Study 33704077 — intervention group
Group type: COMPARATOR
Intervention: Usual care before intervention (UC/IV).
Number of subjects: 119
Study 33704444 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Therapy)
Number of subjects: 2432
Study 33704444 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-detectable viral load
Number of subjects: 2432
Study 33704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician-scored stool consistency using the Bristol Stool Form Scale (BSFS)
Number of subjects: 364
Study 33704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fat
Number of subjects: 364
Study 33704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) scores
Number of subjects: 364
Study 33704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning analyses
Number of subjects: 364
Study 33705389 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucotypes
Number of subjects: 0
Study 33705389 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of continuous glucose monitoring
Number of subjects: 0
Study 33705565 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 2348
Study 33705565 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin solution
Number of subjects: 2348
Study 33705565 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandins
Number of subjects: 2348
Study 33706339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally followed by misoprostol 800 micrograms buccally
Number of subjects: 266
Study 33706343 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System (LNG-IUS)
Number of subjects: 0
Study 33706343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LNG-IUS placement)
Number of subjects: 0
Study 33706813 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, culturally appropriate computerized decision-aid (DA) for lupus patients
Number of subjects: 500
Study 33706813 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized capacity-building activities for lupus DA implementation
Number of subjects: 500
Study 33707216 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (12 weeks, including individualized resistance and aerobic exercises, and telephone health calls for the first 6 weeks)
Number of subjects: 40
Study 33707233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral tilsotolimod (8 mg) with systemic ipilimumab
Number of subjects: 0
Study 33707233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral tilsotolimod
Number of subjects: 0
Study 33707268 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric lung ultrasound (LUS)
Number of subjects: 41
Study 33707402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Recovery Group (n = 19)
Number of subjects: 40
Study 33707402 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Recovery Group (n = 12)
Number of subjects: 40
Study 33707402 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Recovery Group (n = 9)
Number of subjects: 40
Study 33708373 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD3-I score
Number of subjects: 577
Study 33708373 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD2 score
Number of subjects: 577
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 359
Study 33708474 — intervention group
Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 359
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 359
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 359
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 359
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 359
Study 33708474 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate low doses of NOACs
Number of subjects: 359
Study 33708484 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly injections
Number of subjects: 150
Study 33708484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33708520 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 200
Study 33708520 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 33708641 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching monopolar no-touch radiofrequency ablation (RFA)
Number of subjects: 116
Study 33708641 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency ablation (RFA)
Number of subjects: 116
Study 33708641 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching monopolar no-touch RFA
Number of subjects: 116
Study 33708780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (LD-DAC, 5 mg/m²)
Number of subjects: 0
Study 33708965 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel continuation maintenance (DCM) therapy
Number of subjects: 375